Recent investigations have broadened CA125 diagnostic applicability to encompass various gynecological disorders, thereby underscoring its potential—albeit with certain constraints—in discerning between non-malignant conditions such as leiomyomas and adenomyosis, and malignant entities like endometrial carcinoma. This evidence concerns the gene MUC16 and leiomyoma.